Hannam & Partners, a leading independent investment bank, issued an independent research report on Psyence Group.

The report identifies the company as a first mover into the palliative care market supported by natural psilocybin production.

It notes that while Psyence has already generated revenue through its functional mushroom joint venture (Psyence Function) and production facility vertical (Psyence Production), it attributes the lion’s share of Psyence’s value to its drug discovery programme and expects a 450 per cent uplift in share price.

Psyence Group Inc. (PSYG) opened trading at C$0.10

More From The Market Online
Market graph

@ the Bell: Markets hover near all-time highs

A surge in commodity prices helped lift markets trading in Canada’s busiest centre on Friday to nearly reach a new all-time high.

Reliq Health expands contract with U.S. health group

Reliq Health Technologies (TSXV:RHT) reveals it has expanded an existing contract with a large U.S. health group.
The Market Online Video

Advancing an underexplored area of the Yukon with the same geology as B.C’.s Golden Triangle

Graham Downs and Adam Coulter of Cascadia Minerals (TSXV:CAM) discuss promising projects in the Yukon Territory and British Columbia.

@ the Bell: Dow Jones reaches 40,000 milestone

The Dow Jones Industrial Average reached a key milestone – the 40,000 mark, which it had never reached. Canada’s main stock index also rose.